Skip to main content

Table 1 Clinical profile of patients

From: Quantitative characterization of myocardial infarction by cardiovascular magnetic resonance predicts future cardiovascular events in patients with ischemic cardiomyopathy

 

All (n = 86)

Revascularization (n = 35)

No Revascularization (n = 51)

p-value

Age, years

57 ± 12

58 ± 11

57 ± 14

0.32

Gender, male

73 (85%)

32 (91%)

41 (80%)

0.16

History of hypertension

54 (63%)

26 (74%)

28 (55%)

0.07

History of HL

59 (69%)

25 (71%)

34 (67%)

0.64

History of diabetes

24 (28%)

11 (31%)

13 (25%)

0.55

History of smoking

26 (30%)

12 (34%)

14 (27%)

0.50

Beta Blocker Use

62 (78%)

27 (90%)

35 (71%)

0.06

Ace-I or ARB Use

45 (57%)

17 (57%)

28 (57%)

0.36

Coronary anatomy, n (%)

    

1 vessel disease

13 (15%)

3 (9%)

10 (20%)

0.16

2 vessels disease†

24 (28%)

7 (21%)

17 (33%)

0.17

3 vessels disease

49 (57%)

25 (71%)

24 (47%)

0.02

ICD placement (%)

31 (36%)

8 (23%)

24 (47%)

0.02

Scar volume (cm3)

13.7 ± 12.7

14.5 ± 12.0

13.1 ± 13.3

0.60

Scar % of myocardium (%)

8.3 ± 6.9

9.2 ± 7.6

7.8 ± 6.3

0.37

LVEF (%)

26 ± 12

29 ± 13

24 ± 11

0.10

LVEDV (ml%)

231 ± 83

230 ± 97

232 ± 73

0.88

LVESV (ml%)

177 ± 83

173 ± 96

180 ± 74

0.69

LVED mass/volume (g/ml)

0.79 ± 0.30

0.83 ± 0.28

0.77 ± 0.31

0.22

Ant, sep infarct lesion

55 (64%)

23 (66%)

32 (63%)

0.78

Lat infarct lesion

40 (47%)

16 (46%)

24 (47%)

0.53

Inf infarct lesion

63 (73%)

25 (71%)

38 (75%)

0.75

Cardiovascular events

33 (38%)

16 (46%)

17 (33%)

0.24

  1. Values are expressed as a mean ± SD. HL = hypercholesterolemia;
  2. Ace-I = Angiotensin Converting Enzyme – Inhibitor, ARB = Angiotensin Receptor Blocker ICD = implantable cardiac defibrillator; LVEF = left ventricular ejection fraction;
  3. LVEDV = left ventricular end diastolic volume; LVESV = left ventricular end systolic volume;
  4. † 2 vessel disease include P-LAD or LMT.